Mobile

A phase II, controlled, randomized, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSmith...

Update Il y a 4 ans
Reference: EUCTR2006-002680-18

A phase II, controlled, randomized, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in elderly 60 years and older

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the humoral immune response (anti-haemagglutinin) elicited by the low dose influenza vaccine adjuvanted with AS03 and by Fluarix, with the Northern Hemisphere 2006-2007 influenza vaccine composition, 21 days after vaccination.

Inclusion criteria

  • Immunization against influenza in male and female subjects aged 60 years and older

Links